Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.67 |
| ▸ | DRD2 | P14416 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.60 |
| ▸ | MEN1 | O00255 | 6/20 | 0.60 |
| ▸ | HTR1A | P08908 | 1/20 | 0.60 |
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | HTR7 | P34969 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4004525 | 0.87 | HSD11B1 (0.60) | ALDH1A1SMN1; SMN2DRD2KMT2AMEN1 | |
| SCHEMBL4010589 | 0.85 | POLB (0.66) | ALDH1A1DRD2KMT2AMEN1HTR2A | |
| SCHEMBL4009154 | 0.85 | HSD11B1 (0.55) | ALDH1A1SMN1; SMN2DRD2KMT2AMEN1 | |
| SCHEMBL4005357 | 0.83 | HSD11B1 (0.60) | KMT2AMEN1MAPTHSD11B1 | |
| SCHEMBL4005288 | 0.83 | MAPK1 (0.70) | ALDH1A1DRD2KMT2AMEN1HTR2A | |
| SCHEMBL4006346 | 0.83 | HSD11B1 (0.64) | ALDH1A1DRD2HTR2ANPSR1MAPT | |
| SCHEMBL4009209 | 0.82 | HTT (0.59) | ALDH1A1SMN1; SMN2DRD2KMT2AMEN1 | |
| SCHEMBL4010510 | 0.81 | HSD11B1 (0.62) | ALDH1A1DRD2NPSR1HSD11B1KDM4E | |
| SCHEMBL4003800 | 0.81 | HSD11B1 (0.57) | ALDH1A1DRD2KMT2AMEN1MAPT | |
| SCHEMBL6173210 | 0.81 | ALDH1A1 (1.00) | ALDH1A1SMN1; SMN2KMT2AMEN1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1509213-A2 | ACETAMIDES AND BENZAMIDES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | Abbott Laboratories (US) | 2005-03-02 | — | — | EP | claimed |
| US-20040029887-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2004-02-12 | — | — | US | claimed |
| US-20030232836-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2003-12-18 | — | — | US | claimed |
| US-20030229094-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2003-12-11 | — | — | US | claimed |
| WO-2003099266-A2 | ACETAMIDES AND BENZAMIDES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | ABBOTT LABORATORIES (US) | 2003-12-04 | — | — | WO | claimed |
| US-7528134-B2 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20060009461-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | BHATIA PRAMILA A | 2006-01-12 | — | — | US | disclosed |
| EP-1509213-A2 | ACETAMIDES AND BENZAMIDES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | Abbott Laboratories (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20040029887-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2004-02-12 | — | — | US | disclosed |
| US-20030232836-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2003-12-18 | — | — | US | disclosed |
| US-20030229094-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2003-12-11 | — | — | US | disclosed |
| WO-2003099266-A2 | ACETAMIDES AND BENZAMIDES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | ABBOTT LABORATORIES (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229094-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | CATSPER1, CYP19A1, PDE12 | ALDH1A1 88/4885SMN1; SMN2 1213/4885DRD2 1644/4885 |
| US-20040029887-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | CATSPER1, CYP19A1, PDE12 | ALDH1A1 88/4885SMN1; SMN2 1213/4885DRD2 1644/4885 |
| US-20060009461-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | PDE12, NAAA, CYP19A1 | ALDH1A1 193/4885SMN1; SMN2 1699/4885DRD2 1439/4885 |
| US-20030232836-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | CATSPER1, CYP19A1, PDE12 | ALDH1A1 88/4885SMN1; SMN2 1213/4885DRD2 1644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.